Trials / Sponsors / Lyvgen Biopharma Holdings Limited
Lyvgen Biopharma Holdings Limited
Industry · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) Head and Neck Squamous Cell Carcinoma | Phase 2 | 2024-06-21 |
| Recruiting | A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma Soft Tissue Sarcoma | Phase 1 / Phase 2 | 2022-05-25 |
| Completed | Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy Cancer | Phase 1 | 2021-09-29 |
| Completed | Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy Cancer | Phase 1 | 2021-05-14 |
| Active Not Recruiting | Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Met Cancer | Phase 1 | 2020-12-11 |
| Active Not Recruiting | Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Meta Cancer | Phase 1 | 2019-10-31 |